FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:679-681 March 5, 1998 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Estacio, R. O. PubMed Citation

After the introduction of calcium-channel blockers into clinical practice nearly two decades ago, prescriptions for these drugs for the treatment of hypertension increased to the point where they became the most commonly prescribed antihypertensive drugs in the United States, at least as of a few years ago.¹ Although calcium-channel blockers lower blood pressure and are well tolerated, until recently no data were available from randomized clinical trials regarding their effects on morbidity and mortality in patients with hypertension.

In the Systolic Hypertension in Europe (Syst-Eur) trial,² a long-acting member of the dihydropyridine subclass of calcium-channel blockers, nitrendipine, was found to . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Peart, J. N., Headrick, J. P. (2009). Clinical cardioprotection and the value of conditioning responses. Am. J. Physiol. Heart Circ. Physiol. 296: H1705-H1720 [Abstract] [Full Text]  
• Williams, B. (2006). The Year in Hypertension. J Am Coll Cardiol 48: 1698-1711 [Full Text]  
• Williams, B. (2005). Recent hypertension trials: Implications and controversies. J Am Coll Cardiol 45: 813-827 [Abstract] [Full Text]  
• Magee, L. A, Cham, C., Waterman, E. J, Ohlsson, A., von Dadelszen, P. (2003). Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 327: 955- [Abstract] [Full Text]  
• Mcinnes, G. T (2003). `Size is not everything`: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT): The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). British Journal of Diabetes & Vascular Disease 3: 263-267 [Abstract]  
• Pellegrini, F., Belfiglio, M., De Berardis, G., Franciosi, M., Di Nardo, B., Greenfield, S., Kaplan, S. H., Sacco, M., Tognoni, G., Valentini, M., Corrado, D., D'Ettorre, A., Nicolucci, A., for the QuED Study Group, (2003). Role of Organizational Factors in Poor Blood Pressure Control in Patients With Type 2 Diabetes: The QuED Study Group--Quality of Care and Outcomes in Type 2 Diabetes. Arch Intern Med 163: 473-480 [Abstract] [Full Text]  
• Williams, B. (2003). Drug treatment of hypertension. BMJ 326: 61-62 [Full Text]  
• Mulrow, C. D, Pignone, M. (2001). Evidence based management of hypertension: What are the elements of good treatment for hypertension?. BMJ 322: 1107-1109 [Full Text]  
• KASISKE, B. L., CHAKKERA, H. A., ROEL, J. (2000). Explained and Unexplained Ischemic Heart Disease Risk after Renal Transplantation. J. Am. Soc. Nephrol. 11: 1735-1743 [Abstract] [Full Text]  
• Nielsen, B., Flyvbjerg, A. (2000). Calcium channel blockers - the effect on renal changes in clinical and experimental diabetes: an overview. Nephrol Dial Transplant 15: 581-585 [Full Text]  
• Rodby, R. A., Rohde, R. D., Clarke, W. R., Hunsicker, L. G., Anzalone, D. A., Atkins, R. C., Ritz, E., Lewis, E. J. (2000). The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrol Dial Transplant 15: 487-497 [Abstract] [Full Text]  
• Wang, J.-G., Staessen, J. A., Gong, L., Liu, L., for the Systolic Hypertension in China Collaborat, (2000). Chinese Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med 160: 211-220 [Abstract] [Full Text]  
• Staessen, J.A., Birkenhager, W.H, Fagard, R.H. (2000). Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients. Eur Heart J 21: 2-7  
• Grace, A. A., Camm, A.J. (2000). Voltage-gated calcium-channels and antiarrhythmic drug action. Cardiovasc Res 45: 43-51 [Full Text]  
• Davis, T. M. E., Millns, H., Stratton, I. M., Holman, R. R., Turner, R. C., for the UK Prospective Diabetes Study Group, (1999). Risk Factors for Stroke in Type 2 Diabetes Mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 159: 1097-1103 [Abstract] [Full Text]  
• Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Uleri, S., Muggeo, M. (1999). Effect of Chronic Treatment with Lacidipine or Lisinopril on Intracellular Partitioning of Glucose Metabolism in Type 2 Diabetes Mellitus. J. Clin. Endocrinol. Metab. 84: 1544-1550 [Abstract] [Full Text]  
• Osende, J. I., Walker, A. M., Molitch, M. E., Gheorghiade, M., Schrier, R. W., Estacio, R. O., Jeffers, B. W. (1998). Nisoldipine and Myocardial Infarction. NEJM 339: 126-127 [Full Text]